FOLH1 and prostate cancer: When alpha- or auger-emitting PSMA-based radioligands are used, which benefit from a higher linear energy transfer, the radioligand-complex will need to be transported from the endothelial cells into the tumour microenvironment to reach the tumour DNA, such as occurs in prostate cancer.45